Dr Harold J Burstein, Dr Matthew P Goetz, Dr Heather McArthur and Dr Rita Nanda share their perspectives on the evolving therapeutic landscape for patients with breast cancer. CME information and select publications here .
Dr Aaron Lisberg from the University of California, Los Angeles, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publications here .
Dr Kathleen N Moore from OU Health Stephenson Cancer Center in Oklahoma City, Oklahoma, and Dr Matthew A Powell from the Washington University School of Medicine in St Louis, Missouri, discuss recent updates on available and novel treatment strategies for endometrial cancer. CME information and select publications here .
Prof Patrick Neven from University Hospitals Leuven in Leuven, Belgium, discusses recent updates on available and novel treatment strategies with oral SERDs for ER-positive metastatic breast cancer. CME information and select publications here .
Dr John Strickler from Duke University in Durham, North Carolina, discusses the measurement of molecular residual disease and its current and potential role in colorectal cancer risk assessment, surveillance and treatment decision-making. CME information and select publications here .
Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of breast cancer. CME information and select publications here .
Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, discusses recent datasets and their implications for the current and future management of acute myeloid leukemia. CME information and select publications here .
Dr Aditya Bardia and Dr Adam M Brufsky discuss published and emerging datasets investigating the incorporation of antibody-drug conjugates into the treatment of metastatic breast cancer. CME information and select publications here .
Dr Aaron Lisberg from the University of California, Los Angeles discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publications here .
Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, review recent datasets and their significance for the management of various forms of non-Hodgkin lymphoma. CME information and select publications here .
Dr Laura Huppert from the University of California, San Francisco, discusses approved and investigational antibody-drug conjugates in the current and future management of HR-positive and triple-negative metastatic breast cancer. CME information and select publications here .
Dr Jeremy S Abramson from Massachusetts General Hospital in Boston, Dr Jennifer Crombie from Dana-Farber Cancer Institute also in Boston and Dr Laurie H Sehn from the BC Cancer Centre for Lymphoid Cancer in Vancouver, British Columbia, Canada, discuss recent updates on available and novel treatment strategies for follicular lymphoma. CE information and select publications here .
Dr Ghayas Issa from The University of Texas MD Anderson Cancer Center in Houston discusses data guiding the use of menin inhibitors for patients with acute myeloid leukemia and select alterations. CME information and select publications here .
Dr Sara A Hurvitz and Dr Sara M Tolaney summarize the treatment landscape for breast cancer and discuss the implications of clinical findings recently presented at the 2025 ASCO Annual Meeting. CME information and select publications here .
Prof Meletios-Athanasios (Thanos) C Dimopoulos from Alexandra Hospital in Athens, Greece, Dr Hans Lee from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Joseph Mikhael from City of Hope Cancer Center in Phoenix, Arizona, and Dr Noopur Raje from Massachusetts General Hospital in Boston discuss recent updates on available and novel treatment strategies for relapsed/refractory multiple myeloma. CE information and select publications here ....
Dr Kevin Kalinsky from the Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of breast cancer. CME information and select publications here .
Prof Peter Schmid from Barts Cancer Institute in London reviews available efficacy and safety data guiding the optimal management of metastatic triple-negative breast cancer. CME information and select publications here .
Dr Jonathan Strosberg from Moffitt Cancer Center in Tampa, Florida, discusses recent updates on available and novel treatment strategies for extrapulmonary neuroendocrine carcinoma. CME information and select publications here .
Dr Beth Faiman from Case Comprehensive Cancer Center in Cleveland, Ohio, discusses nursing considerations with CAR T-cell therapy for patients with multiple myeloma. NCPD information and select publications here .
Dr Ana C Garrido-Castro and Prof Peter Schmid review patient cases and provide insights regarding the treatment of metastatic triple-negative breast cancer. CME information and select publications here .
Dr Neel Pasricha from the University of California, San Franciso, reviews corneal and other ophthalmic toxicities associated with antibody-drug conjugates and other cancer therapies and strategies for their prevention and management. CME information and select publications here .
Prof Rebecca A Dent from National Cancer Centre Singapore, Dr Hans Lee from Sara Cannon Research Institute in Nashville, Tennessee, Dr Neel Pasricha from the University of California, San Francisco, and Dr Tiffany A Richards from The University of Texas MD Anderson Cancer Center in Houston, discuss strategies to manage ocular toxicities associated with antibody-drug conjugates and other cancer therapies. CME information and select publications here ....
Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of lung cancer. CME information and select publications here .
Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas review available efficacy and safety data guiding the optimal integration of oral SERDs into clinical practice. CME information and select publications here .
Ms Charise Gleason from Emory Healthcare in Atlanta, Georgia, discusses the evolution of first-line therapy for patients with multiple myeloma. NCPD information and select publications here.
Prof Xavier Leleu from Poitiers University Hospital in Poitiers, France, discusses nursing considerations in the treatment of newly diagnosed multiple myeloma. NCPD information and select publications here .
Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses the monitoring, mitigation and management of adverse events with available antibody-drug conjugates and novel strategies incorporating ADCs into the breast cancer treatment paradigm. CME information and select publications here .
Dr Natalie S Callander and Dr Sagar Lonial provide clinical perspectives on the treatment and disease-management course for patients with relapsed/refractory multiple myeloma. CME information and select publications here .
Dr Haley Ellis and Dr James J Harding review actual patient cases and summarize clinical trial findings regarding the treatment of biliary tract cancers. CME information and select publications here .
Dr Sarah Sammons from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses cases and reviews the current management of brain metastases in patients with HER2-positive breast cancer. CME information and select publications here .
